Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

luveltamab tazevibulin (STRO-002)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Sutro Biopharma, Tasly

Drug class:

Microtubule inhibitor, Folate receptor 1-targeted antibody-drug conjugate

Related drugs:

‹

ado-trastuzumab emtansine (97)

eribulin mesylate (47)

brentuximab vedotin (29)

disitamab vedotin (27)

mirvetuximab soravtansine-gynx (16)

enfortumab vedotin-ejfv (14)

cabazitaxel (12)

ixabepilone (6)

LR004-VC-MMAE (5)

PF-06804103 (4)

PF-08046048 (4)

PF-08046047 (4)

belantamab mafodotin-blmf (3)

polatuzumab vedotin-piiq (3)

RGX-019-MMAE (3)

BAY 94-9343 (3)

IMAB027-vcMMAE (2)

PF-06650808 (2)

MF-TTZ-MMAE (1)

PF-06263507 (1)

PF-08046054 (1)

tisotumab vedotin-tftv (1)

estramustine (0)

Nectin-4 ADC (0)

vintafolide (0)

HuMax-AXL-ADC (0)

mebendazole (0)

›

No biomarker	Ovarian Cancer	No biomarker	Ovarian Cancer	STRO-002 Sensitive: B - Late Trials STRO-002 Sensitive : B	STRO-002 Sensitive: B - Late Trials STRO-002 Sensitive : B
No biomarker	Peritoneal Cancer	No biomarker	Peritoneal Cancer	STRO-002 Sensitive: B - Late Trials STRO-002 Sensitive : B	STRO-002 Sensitive: B - Late Trials STRO-002 Sensitive : B
No biomarker	Fallopian Tube Cancer	No biomarker	Fallopian Tube Cancer	STRO-002 Sensitive: B - Late Trials STRO-002 Sensitive : B	STRO-002 Sensitive: B - Late Trials STRO-002 Sensitive : B
FOLR1 expression	Ovarian Cancer	FOLR1 expression	Ovarian Cancer	STRO-002 Sensitive: C2 – Inclusion Criteria STRO-002 Sensitive : C2	STRO-002 Sensitive: C2 – Inclusion Criteria STRO-002 Sensitive : C2
FOLR1 expression	Endometrial Cancer	FOLR1 expression	Endometrial Cancer	STRO-002 Sensitive: C3 – Early Trials STRO-002 Sensitive : C3	STRO-002 Sensitive: C3 – Early Trials STRO-002 Sensitive : C3
FOLR1 expression	Non Small Cell Lung Cancer	FOLR1 expression	Non Small Cell Lung Cancer	bevacizumab + STRO-002 Sensitive: D – Preclinical bevacizumab + STRO-002 Sensitive : D	bevacizumab + STRO-002 Sensitive: D – Preclinical bevacizumab + STRO-002 Sensitive : D
FOLR1 expression	Endometrial Cancer	FOLR1 expression	Endometrial Cancer	bevacizumab + STRO-002 Sensitive: D – Preclinical bevacizumab + STRO-002 Sensitive : D	bevacizumab + STRO-002 Sensitive: D – Preclinical bevacizumab + STRO-002 Sensitive : D
FOLR1 expression	Ovarian Cancer	FOLR1 expression	Ovarian Cancer	bevacizumab + STRO-002 Sensitive: D – Preclinical bevacizumab + STRO-002 Sensitive : D	bevacizumab + STRO-002 Sensitive: D – Preclinical bevacizumab + STRO-002 Sensitive : D